Brilanestrant (Synonyms: ARN-810; GDC-0810)
目录号: PL02948 纯度: ≥99%
CAS No. :1365888-06-7
商品编号 规格 价格 会员价 是否有货 数量
PL02948-2mg 2mg ¥1360.00 请登录
PL02948-5mg 5mg ¥2040.00 请登录
PL02948-10mg 10mg ¥3276.36 请登录
PL02948-50mg 50mg ¥12240.00 请登录
PL02948-100mg 100mg 询价 询价
PL02948-10mM*1mLinDMSO 10mM*1mLinDMSO ¥2005.38 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Brilanestrant
中文别名
(E)-3-[4-[(E)-2-(2-氯-4-氟苯基)-1-(1H-吲唑-5-基)丁-1-烯-1-基]苯基]-2-丙烯酸;GDC-0810
英文名称
Brilanestrant
英文别名
GDC-0810;ARN-810;(E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid;GDC-0810(ARN-810);Brilanestrant;9MM2R1A06R;GDC 0810;Brilanestrant [USAN];ARN810;GDC0810;ARN 810;BURHGPHDEVGCEZ-KJGLQBJMSA-N;BCP24812;BDBM50090462;DB12253;AK174908;B
Cas No.
1365888-06-7
分子式
C26H20ClFN2O2
分子量
446.90
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Brilanestrant (ARN-810; GDC-0810) 是一种可口服的,选择性的雌激素降能器 (selective estrogen receptor degrader),IC50 值为 0.7 nM。
生物活性
Brilanestrant (ARN-810; GDC-0810) is an orally bioavailable selective estrogen receptor degrader (SERD) with IC 50 of 0.7 nM.
性状
Solid
IC50 & Target[1][2]
IC50: 0.7 nM (estrogen receptor)
体外研究(In Vitro)
Brilanestrant (ARN-810; GDC-0810) is a potent ER-α binder (IC50=6.1 nM), a full transcriptional antagonist with no agonism (3× ERE, IC50=2 nM), and displays good potency and efficacy in ER-α degradation (EC50=0.7 nM) and MCF-7 breast cancer cell viability (IC50=2.5 nM) assays.Brilanestrant (ARN-810; GDC-0810) induces a distinct ERα conformation versus tamoxifen and other ER therapeutics, and does not exhibit tamoxifen-like ER agonism in MCF7 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
The pharmacokinetic profile of Brilanestrant (ARN-810) shows it is a olw clearance molecule across species, with good bioavailability (40%-60%). Brilanestrant (ARN-810) (3 mg/kg, p.o.) shows substantial tumor-growth inhibition in a tamoxifen-sensitive MCF-7 xenograft model, while at the highest dose of 100 mg/kg/day, all animals show tumor regression of more than 50% without weight loss.
Brilanestrant (ARN-810) exhibits low clearance (11 mL/min/kg) and 61% oral bioavailability. Brilanestrant (ARN-810) (1-100 mg/kg/day, p.o.) displays dose dependent efficacy in the MCF7 xenograft model. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. By Lai, et al. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. J Med Chem. 2015 Jun 25;58(12):4888-904.
[2]. Joseph JD, et al. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife. 2016 Jul 13;5. pii: e15828. doi: 10.7554/eLife.15828
溶解度数据
In Vitro: DMSO : 100 mg/mL (223.76 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2